DETAILS FOR THIS REVIEW

Study Population: 12 parallel randomized controlled trials with 8,760 adult outpatients taking nonsteroidal anti-inflammatory drugs (NSAIDs) for more than 4 weeks across multiple centers and nations; patients received proton pump inhibitors (PPIs) for prevention of NSAID-induced ulcers or dyspepsia

Efficacy End Points: Global symptoms of dyspepsia (measured continuously and dichotomously by validated scores and scales), ulcer incidence (endoscopically confirmed gastric or duodenal ulcer), quality of life (measured by validated scales)

Harm End Points: Adverse events reported in absolute numbers or proportions and ulcer complications (bleeding and perforation); adverse events included headaches, bronchitis, dizziness, and major cardiovascular events (eg, angina, atrial flutter, coronary artery disease)